Nanfang-Chunfu Children's Institute of Hematology, GoBroad Medical Institute of Hematology(Guangdong Center) is a distinguished medical institution led by Professor Chunfu Li. We focus on the research, diagnosis and treatment of pediatric oncology and hematology. We engage in strategic cooperation with the Mayo Clinic, integrating medical treatment, teaching and scientific research. Boasting 150 standard beds and 36 specialized transplant suites, our hospital has evolved into a prominent, large-scale pediatric Hematopoietic Stem Cell Transplantation(HSCT) center of global stature, which is practically carried out in Dongguan Taixin Hospital. Dongguan Taixin Hospital, situated on Taixin Road in Dongcheng District of Dongguan City, is a privately owned comprehensive hospital with full coverage under the national medical insurance scheme.

Employing a comprehensive diagnostic system alongside state-of-the-art chemical and biomedical technologies, we specialize in the systematic diagnosis and treatment of hematological and immune disorders. In particular, we specialize in HSCT therapy (or BMT) for thalassemia, namely, hematopoietic stem cell transplant or bone marrow transplant in thalassemia. Many experts recognize that HSCT or BMT is an effective treatment for younger thalassemia patients. We have accumulated many successful treatments in the field of pediatric bone marrow transplant, which makes our hospital one of the best pediatric oncology hospitals in the country. We also have specialists for acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMML), acute myeloid leukemia (AML), and other conditions, and equipped a multidisciplinary team for cancer patients, which can better meet the physical and psychological needs of patients and enhance overall treatment outcomes and patient experience. 

From July 2018 to January 22, 2024, Nanfang-Chunfu Children's Institute of Hematology has performed 1,223 hematopoietic stem cell transplantations(HSCTs), among which 69.77% were haploidentical transplants. Of the cases, 347 cases utilized a novel protocol for T-cell depletion in allogeneic HSCT(TDH) which has been extensively applied to treat diseases, such as thalassemia, acute lymphoblastic leukemia, and various immunological disorders.

The medical team from Chunfu Institute has made multiple appearances at the American Society of Hematology Annual Meeting(ASH) and the European Hematology Association Congress (EHA) , delivering presentations and showcasing posters, thereby presenting their research findings to the global academic community. Meanwhile, their research achievements have been published in prestigious hematology journals such as Blood and Leukemia. They have also innovated complementary transplantation strategies, achieving an overall survival rate(OS) of 97.84% for thalassemia patients.